Viatris
Biosimilar developer, United States. 2 development products across 2 molecules: bevacizumab, darbepoetin alfa.
First approval in the Atlas: Sep 2019, Darbepoetin Alfa BS MYL, darbepoetin alfa (PMDA)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved1
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Bevacizumab | Lextemy | · | withdrawn | · | · | · | · |
| Darbepoetin alfa | Darbepoetin Alfa BS MYL | · | · | Sep 2019 | · | · | · |
Month shown is the first approval or registration of that product in that market.
Also holds or markets
Products developed by another company for which Viatris is the licence holder or applicant in one or more markets.
| Molecule | Brand | Market | Holder or applicant | Approved | Developer |
|---|---|---|---|---|---|
| Etanercept | Mylan Pharmaceuticals Private (INN only) | CDSCO | Mylan Pharmaceuticals Private Limited, now Biocon Biologics Limited | Jan 2021 | Lupin |
Chronology
- PMDASep 2019Darbepoetin Alfa BS MYL, darbepoetin alfa
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.